HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schlachetzki, F. Articles by Pardridge, W. M. Search for Related Content PubMed PubMed Citation Articles by Schlachetzki, F. Articles by Pardridge, W. M. Related Collections All Genetics

Gene therapy of the brain

The trans-vascular approach

From the Department of Neurology (Dr. Schlachetzki), University of Regensburg, Germany; and Department of Medicine (Drs. Zhang, Boado, and Pardridge), University of California Los Angeles.

Address correspondence and reprint requests to Dr. William M. Pardridge, UCLA Warren Hall 13-164, 900 Veteran Avenue, Los Angeles, CA 90024; e-mail: wpardridge{at}mednet.ucla.edu

Many chronic neurologic diseases do not respond to small molecule therapeutics, and have no effective long-term therapy. Gene therapy offers the promise of an effective cure for both genetic and acquired brain disease. However, the limiting problem in brain gene therapy is delivery to brain followed by regulation of the expression of the transgene. Present day gene vectors do not cross the blood-brain barrier (BBB). Consequently, brain gene therapy requires craniotomy and the local injection of a viral gene vector. However, there are few brain disorders that can be effectively treated with local injection. Most applications of gene therapy require global expression in the brain of the exogenous gene, and this can only be achieved with a noninvasive delivery through the BBB—the trans-vascular route to brain. An additional consideration is the potential toxicity of all viral and nonviral approaches, which may either integrate into the host genome and cause insertional mutagenesis or cause inflammation in the brain. Nonviral, noninvasive gene therapy of the brain is now possible with the development of a new approach to targeting therapeutic genes to the brain following an IV administration. This approach utilizes genetically engineered molecular Trojan horses, which ferry the gene across the BBB and into neurons. Global and reversible expression of therapeutic genes in the human brain without surgery and without viral vectors is now possible.

Received September 5, 2003. Accepted in final form December 1, 2003.

This article has been cited by other articles:

				R.-Q. Huang, Y.-H. Qu, W.-L. Ke, J.-H. Zhu, Y.-Y. Pei, and C. Jiang Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer FASEB J, April 1, 2007; 21(4): 1117 - 1125. [Abstract] [Full Text] [PDF]

				E. Carro, C. Spuch, J. L. Trejo, D. Antequera, and I. Torres-Aleman Choroid Plexus Megalin Is Involved in Neuroprotection by Serum Insulin-Like Growth Factor I J. Neurosci., November 23, 2005; 25(47): 10884 - 10893. [Abstract] [Full Text] [PDF]